New Two-Target cell therapy tested for tough blood cancer
NCT ID NCT07196124
Summary
This early-stage study is testing a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on cancer cells in patients with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose and see if the treatment causes side effects. Researchers will also check if the modified immune cells can shrink the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.